# Boundless Bio, Inc. Common Stock (BOLD)

> Boundless Bio, Inc. Common Stock (BOLD) trades at $2.46 (-0.81%) as of 11:11:30 AM EDT on Oct 30, 2026, -6.18% over the past month. Market cap is $57.31M, with 4.6 days to cover in short interest.

Canonical: https://massive.com/quote/bold
Data as of: 2026-10-30T15:11:30.000Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$2.46** -0.02 (-0.81%)
As of 11:11:30 AM EDT on Oct 30, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Boundless Bio, Inc. Common Stock (BOLD) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -2.02% |
| 1W | +2.97% |
| 1M | -6.18% |
| YTD | +102.50% |
| 1Y | +73.57% |
| 52-wk range | $0.96 – $3.16 |

From daily closes through Oct 30, 2026.

## Key statistics

Today's trading snapshot for BOLD: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $2.43 – $2.59 |
| Open | $2.53 |
| Prev close | $2.48 |
| Volume | 20.21K |
| Market cap | $57.31M |
| Shares out | 22.75M |

## Valuation and profitability ratios

Valuation and profitability ratios for Boundless Bio, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 0.87 |
| P/FCF | — |
| ROE | -97.0% |
| ROA | -86.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Oct 29, 2026

## Insider trading

[Boundless Bio, Inc. Common Stock (BOLD) insider trading](https://massive.com/quote/bold/insider-trading.md): open-market Form 4 buys and sells by Boundless Bio, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Boundless Bio, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Jun 23, 2026 · Private placement
  “In connection with the execution and delivery of the Merger Agreement, certain institutional and accredited investors entered into a Series A stock purchase agreement with Serapha, pursuant to which such persons invested in a private placement of Serapha's Series A preferred stock for an aggregate purchase price of approximately $138,000,000.”
- Jun 17, 2026 · Annual meeting results
  “At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 15, 2026 (the Meeting), two proposals were voted upon by the Company's stockholders... Each of the director nominees was elected as a Class II director to hold office until the Company's 2029 annual meeting of stockholders.”
- Apr 13, 2026 · Deal termination
  “On April 13, 2026, Boundless Bio, Inc. (the "Company") entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises (the "Lease Termination Agreement") with ARE-10933 North Torrey Pines, LLC ("Landlord"), pursuant to which the Company and Landlord agreed to terminate that certain Lease Agreement dated as of December 20, 2021, as amended by that certain First Amendment to Lease dated as of November 1, 2024 (as amended, the "Lease").”
- Mar 9, 2026 · Director departure
  “Effective March 3, 2026, Christine Brennan, Ph.D. notified the Company of her resignation from the Board of Directors of the Company. Dr. Brennan's resignation was made in connection with her assuming a new role at Johnson & Johnson Development Corporation, and was not the result of any disagreement with the Company.”
- Jun 23, 2025 · Annual meeting results
  “At the annual meeting of stockholders of Boundless Bio, Inc. (the Company) held on June 23, 2025 (the Meeting), two proposals were voted upon by the Company's stockholders... Below is a brief description of, and the final results of the votes for, each proposal.”

## BOLD short interest

How heavily BOLD is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.6 |
| Short interest | 788.48K |
| Avg volume | 170.58K |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## BOLD news

The latest news and headlines about Boundless Bio, Inc. Common Stock (BOLD).

- [Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting](https://www.globenewswire.com/news-release/2026/04/17/3276505/0/en/Boundless-Bio-Presents-Preclinical-Breast-Cancer-Data-from-its-Oral-Kinesin-Degrader-Program-at-2026-AACR-Annual-Meeting.html) · GlobeNewswire Inc. · Apr 17, 2026 · positive sentiment
- [Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights](https://www.globenewswire.com/news-release/2026/03/09/3251668/0/en/Boundless-Bio-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Highlights.html) · GlobeNewswire Inc. · Mar 9, 2026 · positive sentiment
- [Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026](https://www.globenewswire.com/news-release/2026/02/05/3232819/0/en/Boundless-Bio-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html) · GlobeNewswire Inc. · Feb 5, 2026 · positive sentiment
- [Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights](https://www.globenewswire.com/news-release/2025/05/09/3078097/0/en/Boundless-Bio-Reports-First-Quarter-2025-Financial-Results-and-Business-Highlights.html) · GlobeNewswire Inc. · May 9, 2025 · positive sentiment
- [Boundless Bio to Participate in the Needham Virtual Healthcare Conference](https://www.globenewswire.com/news-release/2025/04/03/3054975/0/en/Boundless-Bio-to-Participate-in-the-Needham-Virtual-Healthcare-Conference.html) · GlobeNewswire Inc. · Apr 3, 2025 · positive sentiment

## About Boundless Bio, Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 28 |
| Listed | Mar 28, 2024 |

[Company website](https://www.boundlessbio.com)

## FAQ

### What is the Boundless Bio, Inc. Common Stock (BOLD) stock price today?

Boundless Bio, Inc. Common Stock (BOLD) is trading at $2.46 (-0.81% on the day) as of 11:11:30 AM EDT on Oct 30, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Boundless Bio, Inc. Common Stock?

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer…

### What is the short interest in BOLD?

As of Oct 15, 2026, BOLD has 788.48K shares short and 4.6 days to cover.

### What exchange is BOLD listed on?

Boundless Bio, Inc. Common Stock (BOLD) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time BOLD quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=BOLD`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Boundless Bio, Inc. Common Stock (BOLD) insider trading](https://massive.com/quote/bold/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms